US5334379A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Cytokine and hormone carriers for conjugate vaccines
Assignee: Wyeth Holdings LLC
•
Filing: 1990-07-16
•
Granted: 1994-08-02
•
Expires: 2010-07-16
Abstract
Abstract This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor having immunomodulating activity, wherein the cytokine, lymphokine, hormone or growth factor is capable of modifying immunogenicity of the carbohydrate containing antigen. The cytokine or lymphokine can be an interleukin or an interferon. The immunogenic conjugate can be used in vaccine and co-vaccine formulations.
Inventors
- 👤 Subramonia Pillai
- 👤 Ronald Eby
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:23
CPC Classifications
A; A61; A61K; A61K47/00; A61K47/50; A61K39/00; A61K39/385; A61K47/51; A61K47/62; A61K47/64; A61K47/646; A61K2039/60; A61K2039/6031; Y; Y02; Y02A; Y02A50/00; Y02A50/30; Y10; Y10S; Y10S424/00; Y10S424/831
Claims Analysis
Total Claims: 21
Claim 1
Independent Claim
24 words
An immunogenic conjugate comprising a bacterial capsular polymer bound to a lymphokine selected from the group consisting of interferon, interleukin 1α, interleukin-2β and interleukin-2.
Claim 2
Dependent Claim
24 words
An immunogenic conjugate comprising a bacterial capsular polymer bound to a lymphokine selected from the group consisting of interferon, interleukin 1α, interleukin-2β and interleukin-2.
Claim 3
Dependent Claim
14 words
The conjugate of claim 1, wherein the polymer is covalently bound to the lymphokine.
Claim 4
Dependent Claim
16 words
The conjugate of claim 2, wherein the polymer is bound to the lymphokine by reductive amination.
Claim 5
Dependent Claim
41 words
The conjugate of claim 1, wherein the polymer fragment is derived from Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae, Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae and Clostridium tetani.
Claim 6
Dependent Claim
10 words
The conjugate of claim 4, wherein the polymer is polyribosylribitolphosphate.
Claim 7
Dependent Claim
15 words
The conjugate of claim 4, wherein the fragment or oligomer is derived from Streptococcus pneumoniae.
Claim 8
Dependent Claim
27 words
The conjugate of claim 6, wherein the fragment or oligomer is from serotype 1, 4, 5, 6A, 6B, 9V, 14, 18C, 19F or 23F of S. pneumoniae.
Claim 9
Dependent Claim
22 words
The conjugate of claim 1, wherein the fragment or oligomer is from group A or group C capsular saccharide of N. meningitidis.
Claim 10
Dependent Claim
36 words
A vaccine composition, comprising an immunogenic conjugate, comprising a bacterial capsular polymer bound to a lymphokine selected from the group consisting of interferon, interleukin-1α, interleukin-1β and interleukin-2, in a pharmaceutically acceptable vehicle and an optional adjuvant.
Claim 11
Dependent Claim
36 words
A vaccine composition, comprising an immunogenic conjugate, comprising a bacterial capsular polymer bound to a lymphokine selected from the group consisting of interferon, interleukin-1α, interleukin-1β and interleukin-2, in a pharmaceutically acceptable vehicle and an optional adjuvant.
Claim 12
Dependent Claim
41 words
The vaccine composition of claim 9, wherein the polymer is derived from Haemophilus influenzae, Escherichia coli, Neisseria meningitidis, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis, Vibrio cholerae, Corynebacteria diphtheriae, Neisseria gonorrhoeae, Bordetella pertussis, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae and Clostridium tetani.
Claim 13
Dependent Claim
11 words
The vaccine composition of claim 9, wherein the polymer is polyribosylribitolphosphate.
Claim 14
Dependent Claim
14 words
The vaccine composition of claim 10, wherein the polymer is derived from Streptococcus pneumoniae.
Claim 15
Dependent Claim
28 words
The vaccine composition of claim 12, wherein the polymer is from serotype 1, 4, 5, 6A, 6B , 9V, 14, 18C, 19F or 23 F of S. pneumoniae.
Claim 16
Dependent Claim
21 words
The vaccine composition of claim 10, wherein the polymer is from group A or group C capsular saccharide of N. meningitidis.
Claim 17
Dependent Claim
15 words
The vaccine composition of claim 9, which comprises a mineral suspension of alum as adjuvant.
Claim 18
Dependent Claim
19 words
An immunogenic conjugate comprising polyribosylribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate.
Claim 19
Dependent Claim
19 words
An immunogenic conjugate comprising polyribosylribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate.
Claim 20
Dependent Claim
32 words
A vaccine composition comprising an immunogenic conjugate comprising polyribosylribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate, in a pharmaceutically acceptable vehicle and an optional adjuvant.
Claim 21
Dependent Claim
32 words
A vaccine composition comprising an immunogenic conjugate comprising polyribosylribitolphosphate bound to interleukin-2, wherein interleukin-2 is capable of modifying the immunogenic activity of polyribosylribitolphosphate, in a pharmaceutically acceptable vehicle and an optional adjuvant.
References Cited (Backward Citations)
US4673574A
Cited
US4675382A
Cited
EP0141484A2
Cited
US4761283A
Cited
US4987237A
Cited
EP0158198A1
Cited
US4695624A
Cited
EP0183503A2
Cited
US4766106A
Cited
WO1987000056A1
Cited
US4772685A
Cited
US5013824A
Cited
US4935233A
Cited
US4962188A
Cited
US4820514A
Cited
US4745180A
Cited
US4902505A
Cited
US4801575A
Cited
WO1988000971A1
Cited
US4946945A
Cited
US5039790A
Cited
US5073627A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-08-01 | 1998-01-31 | 1998-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-08-01 | 2002-01-31 | 2002-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-08-01 | 2006-01-31 | 2006-08-02 | $7700.00 | Window Closed / Lapsed |